New York State Common Retirement Fund Purchases 27,758 Shares of RxSight, Inc. (NASDAQ:RXST)

New York State Common Retirement Fund grew its position in RxSight, Inc. (NASDAQ:RXST) by 25.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 135,438 shares of the company’s stock after buying an additional 27,758 shares during the period. New York State Common Retirement Fund’s holdings in RxSight were worth $5,461,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of RXST. Artisan Partners Limited Partnership raised its stake in shares of RxSight by 17.3% in the third quarter. Artisan Partners Limited Partnership now owns 2,437,765 shares of the company’s stock valued at $67,989,000 after purchasing an additional 359,295 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of RxSight by 21.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after acquiring an additional 255,150 shares during the period. Lord Abbett & CO. LLC boosted its position in shares of RxSight by 13.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 1,628,320 shares of the company’s stock valued at $45,414,000 after acquiring an additional 197,099 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in RxSight by 263.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 243,346 shares of the company’s stock valued at $6,787,000 after acquiring an additional 176,451 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in RxSight in the third quarter worth about $3,432,000. Institutional investors own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Oppenheimer boosted their price target on RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Stifel Nicolaus increased their price objective on RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of RxSight in a report on Thursday, April 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $49.63.

RxSight Stock Up 3.4 %

RXST stock opened at $61.68 on Friday. The business has a fifty day moving average price of $52.73 and a 200 day moving average price of $42.81. RxSight, Inc. has a fifty-two week low of $18.09 and a fifty-two week high of $61.85.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. The business had revenue of $28.58 million for the quarter, compared to analysts’ expectations of $28.60 million. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. Equities analysts anticipate that RxSight, Inc. will post -0.94 EPS for the current year.

Insider Buying and Selling at RxSight

In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $56.37, for a total transaction of $563,700.00. Following the completion of the sale, the chief financial officer now owns 13,691 shares in the company, valued at approximately $771,761.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $56.37, for a total value of $563,700.00. Following the sale, the chief financial officer now directly owns 13,691 shares in the company, valued at $771,761.67. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Shelley B. Thunen sold 20,000 shares of RxSight stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $49.90, for a total value of $998,000.00. Following the transaction, the chief financial officer now owns 8,402 shares in the company, valued at $419,259.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 59,490 shares of company stock worth $3,043,578. Company insiders own 21.13% of the company’s stock.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.